Russell Voltin, MD
Psychiatry · South Charleston, WVNPI 1275659096
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 391 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 20.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,613 and has fallen 71.6% since, to $458 in 2025.
Across 391 payments — averaging $17.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Brainsway USA Inc$590
- Otsuka America Pharmaceutical, Inc.$532
- Teva Pharmaceuticals USA, Inc.$505
- Lundbeck LLC$473
- Takeda Pharmaceuticals U.S.A., Inc.$404
- plus $3K from 26 others
Across 2 payments — averaging $48,580 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Brainsway USA Inc$97K
What the payments were for
- Food & beverage$6,76598%
- Education$1652%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 118 | $1,410 |
| Brainsway USA Inc | 9 | $590 |
| Otsuka America Pharmaceutical, Inc. | 32 | $532 |
| Teva Pharmaceuticals USA, Inc. | 21 | $505 |
| Lundbeck LLC | 31 | $473 |
| Takeda Pharmaceuticals U.S.A., Inc. | 27 | $404 |
| Johnson & Johnson | 16 | $394 |
| Alkermes, Inc. | 14 | $339 |
| Harmony Biosciences LLC | 18 | $308 |
| Corium, LLC | 11 | $288 |
| Vanda Pharmaceuticals Inc. | 12 | $245 |
| Tris Pharma Inc | 10 | $209 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 11 | $175 |
| Axsome Therapeutics, Inc. | 8 | $173 |
| Neurocrine Biosciences, Inc. | 8 | $140 |
| Jazz Pharmaceuticals Inc. | 7 | $132 |
| Shire North American Group Inc | 9 | $121 |
| Avanir Pharmaceuticals, Inc. | 7 | $115 |
| Eisai Inc. | 3 | $50 |
| Ironshore Pharmaceuticals Inc. | 3 | $47 |
| Neos Therapeutics, LP | 3 | $46 |
| Supernus Pharmaceuticals, Inc. | 2 | $45 |
| E.r. Squibb & Sons, L.L.C. | 1 | $27 |
| Biogen | 2 | $26 |
| Sage Therapeutics, LLC | 1 | $25 |
| Indivior Inc. | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| Bausch Health US, LLC | 1 | $15 |
| Merck | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Aytu Biopharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,930 in reported general payments places this provider in the 85th percentile of 177 psychiatry providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 43 | $208,374 |
| Wellbutrin XlBupropion Hcl | 16 | $93,759 |
| RexultiBrexpiprazole | 20 | $51,379 |
| VraylarCariprazine Hcl | 37 | $51,123 |
| TrintellixVortioxetine Hydrobromide | 45 | $29,833 |
| AuvelityDextromethorphan Hbr/Bupropion | 36 | $24,081 |
| NuedextaDextromethorphan Hbr/Quinidine | 15 | $14,058 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 211 | $10,346 |
| Lisdexamfetamine Dimesylate | 34 | $6,970 |
| Bupropion XlBupropion Hcl | 314 | $6,067 |
| Escitalopram Oxalate | 580 | $5,665 |
| Trazodone Hcl | 382 | $4,617 |
| Duloxetine Hcl | 174 | $3,941 |
| Clonazepam | 348 | $2,907 |
| Quetiapine Fumarate | 178 | $2,903 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $505 | $208,37443 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $532 | $51,37920 claims |
| AbbVieVraylar | $1,410 | $51,12337 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $404 | $29,83345 claims |
| Axsome Therapeutics, Inc.Auvelity | $173 | $24,08136 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $115 | $14,05815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 177 psychiatry providers in West Virginia.
Other psychiatry in South Charleston
- Daniel ThistlethwaiteSouth Charleston$468K
- Amy WehrleSouth Charleston$9K
- Alexander OtellinSouth Charleston$4K
- Melissa MoodyCharleston$1.2M
- April BaisdenScott Depot$775K
- Ryan WakimWheeling$772K
- Walter ByrdMorgantown$299K
- Fahd MousaCharleston$200K
- Debra StultzBarboursville$173K
- Shahnoor KhanMartinsburg$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.